Explore our recent poster presentation, which dives into a highly sensitive analysis using an EVOSEP-LC-MS/MS assay, with a focus on targeted PD-L1 and PD-1 expression levels to predict responses to immune checkpoint inhibitors (ICIs).
We address the limitations of traditional PD-L1 and PD-1 immunoassays and their uncertain clinical value across tumor types. Through analysis of our robust method against routine immunoassays, and use of Overall Response Rate (ORR), we offer a new perspective on the predictive power of biomarkers for non-small cell lung cancer (NSCLC) therapy.
Download our poster to discover the potential of this innovative approach.
CONTACT US to learn more about Aliri’s extensive experience with this technology.